Brief: PolyPid Announces Exclusive Licensing Agreement With Advanz Pharma
03/08/2022 12:20
Aug 3 (Reuters) - PolyPid Ltd PYPD.O :
* POLYPID ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH
ADVANZ
PHARMA FOR THE COMMERCIALIZATION OF D-PLEX₁₀₀ IN EUROPE
* POLYPID TO POTENTIALLY RECEIVE OVER $110 MILLION IN
UPFRONT AND
MILESTONE PAYMENTS AS WELL AS ROYALTIES ON NET SALES
* POLYPID-CO TO SUPPLY D-PLEX(100) TO ADVANZ PHARMA;WILL BE
ENTITLED TO ROYALTIES ON NET SALES IN DOUBLE-DIGIT PERCENTAGES
OF UP TO MID-TWENTIES
Source text for Eikon: ID:nGNX1VD0SB
Further company coverage: PYPD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Polypid
See all newsPolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA